Fundraising Fox鸿运华宁生物医药
1 known investors
Find your way into 鸿运华宁生物医药
Sign up to see every warm intro you have to 鸿运华宁生物医药
- Paths you didn't know you had: your email and LinkedIn already hold routes to the 鸿运华宁生物医药 team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Gmax Biopharm develops therapeutic monoclonal antibodies targeting G protein-coupled receptors (GPCRs), using proprietary antibody discovery platforms. The company operates in the biotechnology and drug development sector.
Investors · 1
Frequently asked questions
- What does 鸿运华宁生物医药 do?
- Gmax Biopharm develops therapeutic monoclonal antibodies targeting G protein-coupled receptors (GPCRs), using proprietary antibody discovery platforms. The company operates in the biotechnology and drug development sector.
- Who are 鸿运华宁生物医药's investors?
- 鸿运华宁生物医药's investors include EFung Capital.